|
|
| Product Name: | MN58b | | Synonyms: | MN58b;1-[[4-[4-[4-[[4-(dimethylamino)pyridin-1-ium-1-yl]methyl]phenyl]butyl]phenyl]methyl]-N,N-dimethylpyridin-1-ium-4-amine;MN58b,inhibit,Apoptosis,Inhibitor,MN-58b;1,1'-((Butane-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridin-1-ium) bromide;Pyridinium, 1,?1'-?[1,?4-?butanediylbis(4,?1-?phenylenemethylene)?]?bis[4-?(dimethylamino)?-?, bromide (1:2);1,1'-((Butane-1,4-diylbis(4,1-phenylene))bis(methylene))bis(4-(dimethylamino)pyridin-1-ium) bromide | | CAS: | 203192-01-2 | | MF: | C32H40BrN4+ | | MW: | 560.6 | | EINECS: | | | Product Categories: | | | Mol File: | 203192-01-2.mol |  |
| | MN58b Chemical Properties |
| storage temp. | Store at -20°C | | solubility | DMSO:14.71(Max Conc. mg/mL);22.97(Max Conc. mM) | | form | Solid | | color | White to off-white |
| | MN58b Usage And Synthesis |
| Biological Activity | MN58b is a selective choline kinase α (CHKα) inhibitor that inhibits phosphorylcholine synthesis.It reduces cell growth by inducing apoptosis and has antitumor activity. | | in vitro | The IC 50 s of MN58b for parental and Gemcitabine-resistant Suit2 007 cells are 3.14 μM and 0.77 μM, respectively.
It has a marked effect on colony formation at 1 μM, and growth is completely abolished at 5 μM in all the cell lines.
It induces apoptosis and this response correlates with CHKα expression. Cell Viability Assay | Cell Line: | SK-PC-1 , Suit2 008, IMIM-PC2, and RWP-1 cells | | Concentration: | 1 μM, 5 μM | | Incubation Time: | 72 hours | | Result: | Inhibited ce lls growth. | Apoptosis Analysis | Cell Line: | SK-PC-1, Suit2 008, IMIM-PC2, and RWP -1 cells | | Concentration: | 1 μM, 2 μM, 5 μM, 10 μM | | Incubation Time: | 24 and 48 hours | | Result: | Induced cell apoptosis. | < /span> | | in vivo | MN58b (4 mg/kg; intraperitoneal injection; once a day; for 5 days; MF-1 nude mice) treatment significantly decreases phosphomonoesters in both HT29 and MDA-MB-231 xenografts. Phosphocholine levels are found to correlate with choline kinase activities. | Animal Model: | MF-1 nude mice with HT29 or MDA-MB-231 cells | | Dosage: | 4 mg/kg | | Administration: | Intraperitoneal injection; once a day; for 5 days | | Result : | Phosphomonoesters decreased significantly. | | | target | |
| | MN58b Preparation Products And Raw materials |
|